While EBV-based screening approaches, including VCA/EBNA1-IgA serology and plasma EBV DNA quantification, have shown promise in improving early detection and reducing NPC-specific mortality, concerns remain regarding low positive predictive value and variability in laboratory performance. Here, CD79A is linked to nasopharyngeal carcinoma.